Development of a novel nanoparticle vaccine using sialidase against tuberculosis

2023 Fiscal Year Final Research Report

• Project/Area Number: 20K07800
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 52010:General internal medicine-related
• Research Institution: Hamamatsu University School of Medicine
• Principal Investigator: Noriyuki Enomoto 浜松医科大学, 医学部附属病院, 講師 (50436961)
• Co-Investigator(Kenkyū-buntansha): 須田 隆文 浜松医科大学, 医学部, 教授 (30291397) ; 永田 年 浜松医科大学, 医学部, 教授 (90275024)
• Project Period (FY): 2020-04-01 – 2024-03-31
• Keywords: シアリダーゼ / ナノ粒子

Outline of Final Research Achievements

Ovalbumin (OVA)-derived hybrid long epitope peptide, which can induce both cytotoxic T-cell and helper T-cell, were prepared. In addition, this hybrid long epitope peptide was mixed with polylactic coglycolic acid (PLGA) and sialidase, which can degrade a complex of sialic acid/Siglec-G/CD24 and enhance Tall-like receptor signal. Bone marrow-derived dendritic cell (BMDC) was pulsed with this hybrid long epitope peptide/sialidase/PLGA complex, and cocultured with OT-I and OT-II cells. As a results, the tendency that this hybrid long epitope peptide/sialidase/PLGA complex induced more OT-I and OT-II cell proliferation compared to hybrid long epitope peptide/PLGA. However, this difference in the proliferation of OT-I and OT-II cells was not statistically significant. The problem in the interaction between sialidase and PLGA may have existed.

Free Research Field

細胞性免疫学

Academic Significance and Societal Importance of the Research Achievements

シアル酸・Siglec-G・CD24複合体を分解しTLRシグナルを増強するシアリダーゼとの混合が、ナノ粒子ワクチンの有意な増強効果を示せば、新規アジュバントとして様々なワクチンへの応用も可能であると考えられたが、今回の実験では有意差を示す事ができなかった。